Get started
Author

Preetam Gandhi

Observed names: Gandhi, Preetam, P. Gandhi
ORCID: 0000-0003-1774-1369
Observed ORCID: 0000-0003-1774-1369
OpenAlex ID: A5012436243
Triclabendazole in the treatment of human fascioliasis: a review
2019 · Preetam Gandhi, Esther K Schmitt, et al. · Transactions of the Royal Society of Tropical Medicine and Hygiene · 127
PDF
High Prevalence of Plasmodium falciparum K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance After Treatment With Artemether-Lumefantrine
2021 · Judith Straimer, Preetam Gandhi, et al. · The Journal of Infectious Diseases · 123
PDF
Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity
2017 · Michael Huss, Praveen Duhan, et al. · Neuropsychiatric Disease and Treatment · 102
PDF
Efficacy of Cipargamin (KAE609) in a Randomized, Phase II Dose-Escalation Study in Adults in Sub-Saharan Africa With Uncomplicated Plasmodium falciparum Malaria
2021 · Esther K Schmitt, Gilles Ndayisaba, et al. · Clinical Infectious Diseases · 88
PDF
Defining the Antimalarial Activity of Cipargamin in Healthy Volunteers Experimentally Infected with Blood-Stage Plasmodium falciparum
2020 · James S. McCarthy, Azrin N. Abd-Rahman, et al. · Antimicrobial Agents and Chemotherapy · 34
Hepatic safety and tolerability of cipargamin (KAE609), in adult patients with Plasmodium falciparum malaria: a randomized, phase II, controlled, dose-escalation trial in sub-Saharan Africa
2021 · Gilles Ndayisaba, Adoke Yeka, et al. · Malaria Journal · 27
PDF
Long-Term (1 Year) Safety and Efficacy of Methylphenidate Modified-Release Long-Acting Formulation (MPH-LA) in Adults with Attention-Deficit Hyperactivity Disorder: A 26-Week, Flexible-Dose, Open-Label Extension to a 40-Week, Double-Blind, Randomised, Placebo-Controlled Core Study
2014 · Y. Ginsberg, T. Arngrim, et al. · CNS Drugs · 19
PDF
Open-Label Dose Optimization of Methylphenidate Modified Release Long Acting (MPH-LA): A Post Hoc Analysis of Real-Life Titration from a 40-Week Randomized Trial
2014 · Michael Huss, Ylva Ginsberg, et al. · Clinical Drug Investigation · 14
PDF
Defining the next generation of severe malaria treatment: a target product profile
2024 · Jane Achan, Aïssata Barry, et al. · Malaria Journal · 13
PDF
Pharmacokinetics, safety and efficacy of an optimized dose of artemether–lumefantrine in the treatment of acute uncomplicated Plasmodium falciparum malaria in neonates and infants of less than 5 kg body weight: a multicentre, open-label, single-arm phase 2/3 study (CALINA)
2025 · Gildas Wounounou, Alfred B. Tiono, et al. · Tropical Medicine and Health · 2
PDF
P.1.g.013 Efficacy and safety of methylphenidate modified release long-acting after reinstatement of therapy in placebo treated patients
2014 · M. Huss, Y. Ginsberg, et al. · European Neuropsychopharmacology · 2
P.7.d.009 Methylphenidate hydrochloride modified release improved inattention and hyperactivity/impulsivity scores in adult ADHD patients
2013 · M. Huss, Y. Ginsberg, et al. · European Neuropsychopharmacology · 2
Global impact of human fasciolosis.
2021 · Preetam Gandhi, Richa Chandra, et al. · CABI eBooks · 1
P.1.g.014 Added benefits of long-term treatment of methylphenidate modified-release long-acting formulation in adults with ADHD
2014 · M. Huss, Y. Ginsberg, et al. · European Neuropsychopharmacology · 1
P.7.d.005 Methylphenidate hydrochloride modified release led to a beneficial impact on family-, work- and social life in adult ADHD patients
2013 · M. Huss, Y. Ginsberg, et al. · European Neuropsychopharmacology · 1
Socioeconomic Impact of Artemether–Lumefantrine in Malaria Treatment across Sub-Saharan Africa: A Model-Based Historical Analysis with 2022 as Reference Year
2026 · Adnan Atitallah, Platon Peristeris, et al. · American Journal of Tropical Medicine and Hygiene
PA-282 Juvenile toxicity program to support use of Cipargamin (KAE609) in paediatric patients with severe malaria
2023 · Sabine Pfeffer, Nekoye Otsyula, et al.
PDF
EPA-0627 - Safety profile of methylphenidate hydrochloride-modified release (MPH-LA) in adults and children with attention deficit hyperactivity disorder
2014 · Y. Ginsberg, T. Arngrim, et al. · European Psychiatry
EPA-0513 – Methylphenidate hydrochloride modified release (mph-la) maintained efficacy over long-term in the treatment of adult attention deficit hyperactivity disorder (adhd)
2014 · Y. Ginsberg, T. Tvedten, et al. · European Psychiatry
EPA-0626 – Long-term safety of methylphenidate hydrochloride modified release (MPH-LA) in the treatment of attention deficit hyperactivity disorder (ADHD) in adults
2014 · Y. Ginsberg, T. Tvedten, et al. · European Psychiatry
Works count: 23
Citation count: 556
H-index: 9
I10-index: 9
Year
Topic
Type